Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch

Biomaterials

Volumn 57, Issue , 2015, Pages 50-58

  Hirobe, Sachiko ^a   Azukizawa, Hiroaki ^b   Hanafusa, Takaaki ^b   Matsuo, Kazuhiko ^a   Quan, Ying Shu ^c   Kamiyama, Fumio ^c   Katayama, Ichiro ^b   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c NONE   (Japan)

Author keywords

Drug delivery; ELISA; Hyaluronic acid; Immune response

Indexed keywords

ANTIGENS; DISSOLUTION; DRUG DELIVERY; HYALURONIC ACID; IMMUNE SYSTEM; MAMMALS; NEEDLES; ORGANIC ACIDS; STRAIN; SYSTEM STABILITY;

CONVENTIONAL INJECTIONS; ELISA; IMMUNE RESPONSE; INFLUENZA VACCINES; MICRONEEDLE PATCHES; STABILITY ASSESSMENT; TRANSCUTANEOUS IMMUNIZATIONS; TRANSCUTANEOUS VACCINATIONS;

VACCINES;

HYALURONIC ACID; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; HEMAGGLUTININ;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALE; MICRONEEDLE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSCUTANEOUS INFLUENZA VACCINATION; ADVERSE EFFECTS; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; CHICKEN; DEVICES; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; SOLUBILITY; TRANSDERMAL PATCH; YOUNG ADULT;

MUS;

ADMINISTRATION, CUTANEOUS; ADULT; ANIMALS; ANTIBODY FORMATION; CHICKENS; HEMAGGLUTININS; HUMANS; HYALURONIC ACID; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SOLUBILITY; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84928940964     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.007     Document Type: Article

References (17)

1. Maher B., Butler D. Swine flu: one killer virus, three key questions. Nature 2009, 462:154-157.
2. Valadas E., Antunes F. Tuberculosis, a re-emergent disease. Eur J Radiol 2005, 55:154-157.
3. Zhu Q., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009, 106:7968-7973.
4. Sullivan S.P., Koutsonanos D.G., Del Pilar Martin M., Lee J.W., Zarnitsyn V., Choi S.O., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16:915-920.
5. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
6. Hirobe S., Azukizawa H., Matsuo K., Zhai Y., Quan Y.S., Kamiyama F., et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res 2013, 30:2664-2674.
7. Matsuo K., Yokota Y., Zhai Y., Quan Y.S., Kamiyama F., Mukai Y., et al. Alow-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. JControl Release 2012, 161:10-17.
8. Matsuo K., Hirobe S., Yokota Y., Ayabe Y., Seto M., Quan Y.S., et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. JControl Release 2012, 160:495-501.
9. Ainai A., Tamura S., Suzuki T., Ito R., Asanuma H., Tanimoto T., et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. JMed Virol 2012, 84:336-344.
10. Lee Y.T., Kim K.H., Ko E.J., Lee Y.N., Kim M.C., Kwon Y.M., et al. New vaccines against influenza virus. Clin Exp Vaccine Res 2014, 3:12-28.
11. Fries L.F., Smith G.E., Glenn G.M. Arecombinant viruslike particle influenza A (H7N9) vaccine. NEngl J Med 2013, 369:2564-2566.
12. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
13. Wong S.S., Webby R.J. Traditional and new influenza vaccines. Clin Microbiol Rev 2013, 26:476-492.
14. Hirobe S., Okada N., Nakagawa S. Transcutaneous vaccines-current and emerging strategies. Expert Opin Drug Deliv 2013, 10:485-498.
15. Matsuo K., Hirobe S., Okada N., Nakagawa S. Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine 2013, 31:2403-2415.
16. Celli S., Albert M.L., Bousso P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nat Med 2011, 17:744-749.
17. Ouchi T., Kubo A., Yokouchi M., Adachi T., Kobayashi T., Kitashima D.Y., et al. Langerhans cell antigen capture through tight junctions confers preemptive immunity in experimental staphylococcal scalded skin syndrome. JExp Med 2011, 208:2607-2613.